Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

By Yahoo! Finance   |   1 month ago
Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

The 908 unique patient enrollments for Yorvipa exclude cumulative scripts. About 20% are existing patients, and insurance approvals are estimated at 4 to 8 weeks. Patient numbers outside the US are increasing as expected, and many new patients are likely uncontrolled on standard therapy.

Read More

Did you find this insightful?